76.00MMarket Cap-686P/E (TTM)
2.1474High2.0600Low371.16KVolume2.0800Open2.0900Pre Close780.24KTurnover1.39%Turnover RatioLossP/E (Static)35.85MShares4.450052wk High8.35P/B56.75MFloat Cap1.820052wk Low--Dividend TTM26.77MShs Float13678193.1609Historical High--Div YieldTTM4.18%Amplitude1.2500Historical Low2.1020Avg Price1Lot Size
Cellectar BioSciences Stock Forum
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Cellectar Biosciences (NASDAQ: CLRB) announced two presentations on iopofosine I 131 at the 12th International Workshop on Waldenstrom's Macroglobulinemia in Prague.
The first presentation by Dr. Jorge Castillo will showcase a case study of complete central nervous system clearance in a patient with Bing-Neel Syndrome (BNS), a rare compli...
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences (NASDAQ: CLRB) has formed a strategic partnership with City of Hope Cancer Center to evaluate the efficacy of its lead drug, iopofosine I 131, in treating mycosis fungoides (MF), a rare form of non-Hodgkin's lymphoma (NHL). This collaboration aims to initiate trials with around 10 patients by late 2024 or early 202...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
4 MINUTES AGO, 6:40 AM EST
VIA GLOBENEWSWIRE
No comment yet